Skip to main content
. 2020 Nov 9;43(11):1144–1161. doi: 10.1007/s12272-020-01281-8

Table 1.

Inhibitors targeting UPS components in clinical trials

graphic file with name 12272_2020_1281_Tab1a_HTML.jpg

graphic file with name 12272_2020_1281_Tab1b_HTML.jpg

graphic file with name 12272_2020_1281_Tab1c_HTML.jpg

graphic file with name 12272_2020_1281_Tab1d_HTML.jpg

AML acute myeloid leukemia, NSCLC non-small cell lung cancer, ALL acute lymphoblastic leukemia, MM multiple myeloma, APL acute promyelocytic leukemia